Erlotinib for Non‐Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101)
K Nosaki, T Yamanaka, A Hamada, Y Shiraishi… - The …, 2020 - academic.oup.com
… this study suggests erlotinib treatment is active for LM. Our findings suggest that erlotinib could
be a useful treatment option … , gefitinib, or afatinib) are effective for treating leptomeningeal …
be a useful treatment option … , gefitinib, or afatinib) are effective for treating leptomeningeal …
Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non–small-cell lung cancer harboring …
Y Zenke, K Yoh, S Matsumoto, S Umemura, S Niho… - Clinical Lung Cancer, 2016 - Elsevier
… ) harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution.
The … I study in the Japanese population, the recommended doses of gefitinib and erlotinib are …
The … I study in the Japanese population, the recommended doses of gefitinib and erlotinib are …
Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer
F Nurhayati, Y Anggriani, E Syahruddin… - Journal of Applied …, 2021 - japsonline.com
… The results of the study show that afatinib therapy was superior to erlotinib and gefitinib as
first-line therapy for NSCLC that is EGFR (+). However, afatinib caused more side effects than …
first-line therapy for NSCLC that is EGFR (+). However, afatinib caused more side effects than …
Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer
AM Czarnecka, P Korzeń… - Oncology …, 2016 - spandidos-publications.com
… study is the first to report a case of pancreatic cancer treated with … therapy of low-dose
gemcitabine (1,000 mg/m2) and erlotinib… The EGFR kinase inhibitors, erlotinib and gefitinib, have …
gemcitabine (1,000 mg/m2) and erlotinib… The EGFR kinase inhibitors, erlotinib and gefitinib, have …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
… In this study, 59.6% and 49.8% of afatinib-treated patients survived for at least 24 and 30 …
It is known that 50%‒60% of patients treated with erlotinib or gefitinib develop T790M-positive …
It is known that 50%‒60% of patients treated with erlotinib or gefitinib develop T790M-positive …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an …
H Saito, T Fukuhara, N Furuya, K Watanabe… - The Lancet …, 2019 - thelancet.com
… the activity of erlotinib plus bevacizumab as first-line treatment for … of erlotinib plus bevacizumab
in this study and the JO25567 … plus gefitinib treatment relative to gefitinib monotherapy. …
in this study and the JO25567 … plus gefitinib treatment relative to gefitinib monotherapy. …
[HTML][HTML] Symptom and quality of life improvement in LUX-Lung 8, an open-label phase III study of second-line afatinib versus erlotinib in patients with advanced …
E Felip, V Hirsh, S Popat, M Cobo, A Fülöp, C Dayen… - Clinical Lung Cancer, 2018 - Elsevier
… using the European Organization for Research and Treatment of Cancer QoL questionnaire
… consensus regarding the effect of gefitinib on HRQoL in randomized studies. Some phase III …
… consensus regarding the effect of gefitinib on HRQoL in randomized studies. Some phase III …
[HTML][HTML] Retrospective Evaluation of Drug-Drug Interactions With Erlotinib and Gefitinib Use in the Military Health System
TLT Luong, CN Powers, BJ Reinhardt… - Federal …, 2023 - ncbi.nlm.nih.gov
… discontinuing erlotinib or gefitinib treatment, respectively. Each patient had 1 to 104 (completed …
Thirty-nine patients (10%) in this study were prescribed erlotinib for off-label indications. …
Thirty-nine patients (10%) in this study were prescribed erlotinib for off-label indications. …
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label …
WZ Zhong, Q Wang, WM Mao, ST Xu, L Wu… - The Lancet …, 2018 - thelancet.com
… We retrieved reports for two randomised trials—one of gefitinib (BR19) and one of erlotinib
(RADIANT)—in which an EGFR tyrosine kinase inhibitor was compared with placebo as …
(RADIANT)—in which an EGFR tyrosine kinase inhibitor was compared with placebo as …
[HTML][HTML] The role of brain radiotherapy before first-line afatinib therapy, compared to gefitinib or erlotinib, in patients with EGFR-mutant non-small cell lung cancer
HA Jung, S Park, SH Lee, JS Ahn, MJ Ahn… - … Res Treat, 2023 - synapse.koreamed.org
… who started first-G EGFR-TKIs (gefitinib or erlotinib) or afatinib as first-line therapy were
retrospectively analyzed. This study compared overall survival and intracranial progression-free …
retrospectively analyzed. This study compared overall survival and intracranial progression-free …